Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109(1):74–103.

Article  CAS  PubMed  Google Scholar 

Lyu X, Zhao Q, Hui J, Wang T, Lin M, Wang K, et al. The global landscape of approved antibody therapies. Antib Ther. 2022;5(4):233–57.

CAS  PubMed  PubMed Central  Google Scholar 

Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs. 2024;16(1):2297450.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol. 2015;28(3):133–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–44.

Article  PubMed  PubMed Central  Google Scholar 

Abdeldaim DT, Schindowski K. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics. 2023;15(10): 2402

Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52(2):83–124.

Article  CAS  PubMed  Google Scholar 

Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development. Clin Transl Sci. 2018; 6:540-552

Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301–19.

Article  CAS  PubMed  Google Scholar 

Bice JB, Leechawengwongs E, Montanaro A. Biologic targeted therapy in allergic asthma. Ann Allergy Asthma Immunol. 2014;112(2):108–15.

Article  CAS  PubMed  Google Scholar 

Che Y, Gribenko AV, Song X, Handke LD, Efferen KS, Tompkins K, et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci Transl Med. 2023;15(693):eade6422.

Article  CAS  PubMed  Google Scholar 

Mullen TE, Abdullah R, Boucher J, Brousseau AS, Dasuri NK, Ditto NT, et al. Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential. Antib Ther. 2021;4(3):185–96.

CAS  PubMed  PubMed Central  Google Scholar 

Hutchings CJ, Colussi P, Clark TG. Ion channels as therapeutic antibody targets. MAbs. 2019;11(2):265–96.

Article  CAS  PubMed  Google Scholar 

Hutchings CJ, Koglin M, Olson WC, Marshall FH. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017;16(9):661.

Article  CAS  PubMed  Google Scholar 

Kubota Y, Shitara K. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Ther Adv Med Oncol. 2024;16:17588359231217968.

Article  PubMed  PubMed Central  Google Scholar 

Douthwaite JA, Finch DK, Mustelin T, Wilkinson TC. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol Ther. 2017;169:113–23.

Article  CAS  PubMed  Google Scholar 

Garaeva AA, Oostergetel GT, Gati C, Guskov A, Paulino C, Slotboom DJ. Cryo-EM structure of the human neutral amino acid transporter ASCT2. Nat Struct Mol Biol. 2018;25(6):515–21.

Article  CAS  PubMed  Google Scholar 

Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S. G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. Signal Transduct Target Ther. 2024;9(1):88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2017;16(1):19–34.

Article  CAS  PubMed  Google Scholar 

Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for engineering therapeutics. Antibodies (Basel). 2019;8(4): 55.

Ayyar BV, Arora S, O’Kennedy R. Coming-of-Age of Antibodies in Cancer Therapeutics. Trends Pharmacol Sci. 2016;37(12):1009–28.

Article  CAS  PubMed  Google Scholar 

O’Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, et al. Development of a Novel CLDN18.2-directed monoclonal antibody and antibody-drug conjugate for treatment of CLDN18.2-positive cancers. Mol Cancer Ther. 2023;22(12):1365–75.

Article  CAS  PubMed  Google Scholar 

Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol. 2009;183(7):4782–91.

Article  CAS  PubMed  Google Scholar 

Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, et al. FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and sezary syndrome. Clin Cancer Res. 2019;25(24):7275–80.

Article  CAS  PubMed  Google Scholar 

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–204.

Article  CAS  PubMed  Google Scholar 

Dolgin E. First GPCR-directed antibody passes approval milestone. Nat Rev Drug Discov. 2018;17(7):457–9.

Article  CAS  PubMed  Google Scholar 

Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodriguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–44.

Article  CAS  PubMed  Google Scholar 

Kumar A, Planchais C, Fronzes R, Mouquet H, Reyes N. Binding mechanisms of therapeutic antibodies to human CD20. Science. 2020;369(6505):793–9.

Article  CAS  PubMed  Google Scholar 

Egelman EH. The current revolution in Cryo-EM. Biophys J. 2016;110(5):1008–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghosh E, Kumari P, Jaiman D, Shukla AK. Methodological advances: the unsung heroes of the GPCR structural revolution. Nat Rev Mol Cell Biol. 2015;16(2):69–81.

Article  CAS  PubMed  Google Scholar 

Nguyen PT, Harris BJ, Mateos DL, Gonzalez AH, Murray AM, Yarov-Yarovoy V. Structural modeling of ion channels using AlphaFold2, RoseTTAFold2, and ESMFold. Channels (Austin). 2024;18(1):2325032.

Article  PubMed  Google Scholar 

McCusker EC, Bane SE, O’Malley MA, Robinson AS. Heterologous GPCR expression: a bottleneck to obtaining crystal structures. Biotechnol Prog. 2007;23(3):540–7.

Article  CAS  PubMed  Google Scholar 

Kaipa JM, Krasnoselska G, Owens RJ, van den Heuvel J. Screening of membrane protein production by comparison of transient expression in insect and mammalian cells. Biomolecules. 2023;13(5): 817.

Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485(7397):207–12.

Article  CAS  PubMed  PubMed Central